Quantum Biopharma (QNTM) Amortization (2019 - 2026)

Quantum Biopharma has disclosed Amortization across 8 years of filings, most recently posting -$13.8 million for Q1 2026.

• Amortization for Q1 2026 came in at -$13.8 million, down 57.37% year-over-year; the trailing twelve-month figure through Mar 2026 was -$37.0 million (down 81.97% YoY), and the FY2024 annual result was $12.1 million, down 6.63% from the prior year.
• Amortization came in at -$13.8 million for Q1 2026 at Quantum Biopharma, down from -$4.7 million in the prior quarter.
• In the past five years, Amortization ranged from a high of $55.7 million in Q1 2022 to a low of -$13.8 million in Q1 2026.
• The 5-year median for Amortization is $11.1 million (2024), against an average of $14.0 million.
• Across the five-year window, Amortization surged 285.82% in 2024 and plunged 317.89% in 2025, its largest moves.
• Quantum Biopharma's Amortization stood at $38.4 million in 2022, then sank by 66.39% to $12.9 million in 2023, then retreated by 6.63% to $12.1 million in 2024, then plunged by 139.39% to -$4.7 million in 2025, then tumbled by 189.7% to -$13.8 million in 2026.
• The last three Amortization figures came in at -$13.8 million (Q1 2026), -$4.7 million (Q3 2025), and -$9.8 million (Q2 2025), per Business Quant data.